A Phase 2 interventional study of PF-07275315 and PF-07264660 in Atopic Dermatitis, sponsored by Pfizer. Active, not recruiting at 96 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 9th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 45th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Pfizer · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 18 · Phase 4 2
First in 2009; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 121 across the 47 interventional studies, 150 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Dermatitis, Atopic by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06899204PfizerReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | 2027-02-15 |
| NCT06564389PfizerFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | 2027-06-02 |
| NCT07887867PfizerA Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | 2027-10-01 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Dermatitis, Atopic by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
This study is seeking participants who:
In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied.
PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage.
The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective.
Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet the following AD criteria:
Clinical diagnosis of chronic atopic dermatitis:
Other Inclusion Criteria:
Exclusion Criteria:
- Medical Conditions:
Any of the following acute or chronic infections or infection history:
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Prior/Concomitant Therapy:
Phototherapy narrowband UVB (NB UVB) or broadband phototherapy or regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks prior to Day 1.
- Prior/Concurrent Clinical Study Experience:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stage 1 PF-07275315 Injections over 12 weeks
Drug: PF-07275315
Stage 1 PF-07264660 Injections over 12 weeks
Drug: PF-07264660
Stage 1 Placebo Injections over 12 weeks
Other: Placebo
Stage 2 PF-07275315 Injections over 12 weeks.
Drug: PF-07275315
Stage 2 PF-07275315 Injections over 12 weeks.
Drug: PF-07275315
Stage 2 PF-07275315 Injections over 12 weeks.
Drug: PF-07275315
Stage 2 PF-07275315 or PF-07264660 Injections over 12 weeks.
Drug: PF-07275315 · Drug: PF-07264660
Stage 2 Placebo Injections over 12 weeks.
Other: Placebo
Stage 3 Placebo Injections for 16 weeks followed by PF-07275315 Injections for 16 weeks.
Drug: PF-07275315 · Other: Placebo
Stage 3 PF-07275315 Injections for 32 weeks.
Drug: PF-07275315
Stage 4 PF-07264660 Injections for 12 weeks
Drug: PF-07264660
Stage 4 PF-07264660 Injections for 12 weeks
Drug: PF-07264660
Stage 4 PF-07264660 Injections for 12 weeks
Drug: PF-07264660
Stage 2 Placebo Injections for 12 weeks
Other: Placebo
subcutaneous injection
subcutaneous injection
subcutaneous injection
The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.
EASI75 (≥75% improvement from baseline) at Week 16
Time frame: Week 16
The number and % of participants achieving vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points
vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points
Time frame: Screening through study completion, an average of 36 weeks.
The number and % of participants achieving EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16
EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16
Time frame: All scheduled timepoints other than Week 16, screening through study completion, an average of 36 weeks.
The number and % of participants achieving a Percent change from baseline in EASI total score at scheduled time points
Percent change from baseline in EASI total score at scheduled time points
Time frame: Screening through study completion, an average of 36 weeks.
The number and % of participants with treatment emergent AEs
Incidence of treatment emergent AEs
Time frame: Screening - Week 36
The number and % of participants with clinically significant changes in vital signs
Incidence of clinically significant changes in vital signs
Time frame: Screening - Week 36
The number and % of participants with clinically significant changes in ECG
Incidence of clinically significant changes in ECG
Time frame: Screening - Week 36
The number and % of participants with clinically significant changes in laboratory tests
Incidence of clinically significant changes in laboratory tests
Time frame: Screening - Week 36
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Aug 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 38 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Nov 2026 and completion Mar 2027 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tilrekimig · Ompekimig